Comparison of the clinicopathological characteristics between mixed medullary and papillary thyroid carcinoma and medullary thyroid carcinoma coexistent with papillary thyroid carcinoma
10.3760/cma.j.cn113855-20200706-00537
- VernacularTitle:甲状腺混合性髓样-乳头状癌与甲状腺髓样癌合并乳头状癌的临床病理特征比较
- Author:
Songfeng WEI
1
;
Pingping WANG
;
Runfen CHENG
;
Jingzhu ZHAO
;
Yi PAN
;
Xiangqian ZHENG
;
Yigong LI
;
Yang YU
;
Ming GAO
Author Information
1. 天津医科大学肿瘤医院甲状腺颈部肿瘤科 国家肿瘤临床诊治中心 天津市肿瘤防治重点实验室 300060
- Keywords:
Thyroid neoplasms;
Carcinoma, medullary;
Carcinoma, papillary;
Pathology, clinical;
Calcitonin
- From:
Chinese Journal of General Surgery
2021;36(6):405-409
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the difference of clinicopathological characteristics between mixed medullary and papillary carcinoma of thyroid and medullary carcinoma coexistent with papillary carcinoma.Method:The clinicopathological data of 3 MMPTC cases and 9 MTC-PTC cases treated at Tianjin Medical University Cancer Institute & Hospital during the past ten years were retrospectively analyzed. The differences in clinical characteristics, pathological characteristics, immunohistochemistry results, treatment and prognosis of the two groups were compared.Results:In the MMPTC group, the median onset-age was 59 years old. 3 patients were all medullary carcinoma colliding with micropapillary carcinoma. The immunohistochemistry results showed that medullary carcinoma and papillary carcinoma showed their distinctive immunohistochemical characteristics. The lymph node metastasis rate was 66.7% (2/3). In MTC-PTC group, the median onset-age was 55; 8 out of 9 patients had an increased preoperative calcitonin level. Medullary carcinoma and papillary carcinoma showed their distinctive immunohistochemical characteristics. Four out of the 9 cases had lymph node metastasis.Conclusion:Compared with MTC-PTC, MMPTC is more common in middle-aged and elder patients, with higher lymph node metastasis rate. The pathogenesis of MTC-PTC is similar to papillary thyroid carcinoma, and the treatment should be individualized. The prognosis of these two groups of patients is fair.
